Pibrentasvir / Glecaprevir - induced cholestatic jaundice in a HCV patient with renal failure. A case presentation.

Pibrentasvir / Glecaprevir - induced cholestatic jaundice in a HCV patient with renal failure. A case presentation. Curr Drug Saf. 2018 Nov 15;: Authors: Caroleo B, Caroleo MC, Cimellaro A, Colangelo L, Perticone M, Di Mizio G, De Sarro G, Gallelli L Abstract Direct-acting a antiviral (DAA) are currently used in the treatment of chronic HCV infection. In patients with renal failure with Elbasvir/Grazoprevir (genotype 1 and 4) or Pibrentasvir/Glecaprevir (genotype 1-6) is advised and these documented both good safety and efficacy. In this manuscript we reported the development of cholestatic jaundice, during Pibrentasvir/Glecaprevir treatment, in a 86-year-old male with chronic HCV (genotype 2) infection and renal failure. At examination patient was jaundiced and suffered of a severe itch. Ultrasound and laboratory findings excluded a liver failure (e.g. liver or pancreatic cancer, liver lithiasis) while Naranjo probability scale suggested a probable (score 6) association between cholestatic janduice and Pibrentasvir/Glecaprevir. About 4 weeks after drug discontinuation we documented an improvement in both jaundice and itch, with a normalization in bilirubin values (total bilirubin: 0.96). HCV-RNA was undetected (ND) as also documented from a new analysis performed on June 15,2018. It is worth mentioning that although we reported the development of cholestatic jaundice upon treatment with Glecaprevir/Pibrentasvir we recorded a clinica...
Source: Current Drug Safety - Category: Drugs & Pharmacology Authors: Tags: Curr Drug Saf Source Type: research